Organising Committee
Aleksander Krag
Odense, Denmark
Brian Lee
Los Angeles, USA
Jessica Mellinger
Ann Arbor, USA
Mads Israelsen
Odense, Denmark
Scientific Advisory Board
Juan Pablo Arab
Richmond, USA
Christophe Moreno
Bruxelles, Belgium
Ashwani Singal
Louisville, USA
Faculty
Juan G Abraldes
Edmonton, Canada
Gro Askgaard
Køge, Denmark
Ramon Bataller
Barcelona, Spain
Paul N Brennan
Dundee, Scotland
Luis Antonio Diaz
San Diego, USA
Sven Francque
Antwerp, Belgium
Giacomo Germani
Padova, Italy
Susana G Rodrigues
Bern, Schweiz
Camilla Dalby Hansen
Odense, Denmark
Peter Jepsen
Aarhus, Denmark
Morten Karsdal
Nordic Bioscience
Carolin Lackner
Graz, Austria
Michelle Long
Novo Nordisk
Alexandre Louvet
Lille, France
Mattias Mandorfer
Vienna, Austria
Thomas Marjot
London, United Kingdom
Gautam Mehta
London, United Kingdom
Mack Mitchell
Dallas, USA
Mazen Noureddin
Houston, USA
Richard Parker
Leeds, United Kingdom
Elisa Pose
Barcelona, Spain
Mary Rinella
Chicago, USA
Carolin Schneider
Aachen, Germany
Horia Stefanescu
Cluj-Napoca, Romania
Stefan Stender
Copenhagen, Denmark
Frank Tacke
Berlin, Germany
Maja Thiele
Copenhagen, Denmark
Nikolaj Torp
Odense, Denmark
Emmanuel Tsochatzis
London, UK
Nikhil Vergis
GSK
Gerald Scott Winder
Detroit, USA
Zobair M Younossi
Washington, USA
Ashwani Singal
Louisville, USA
Dr. Singal is a professor of medicine at the University of Louisville School of Medicine, Director of clinical trials program in liver diseases, transplant hepatologist at the Jewsih hospital and Trager Transplant Center in Louisville KY. In addition, he is a research scientist at the Robley Rex VA Medical Center in Louisville, KY, USA.
With clinical and translational research interests in alcoholic and non-alcoholic fatty liver diseases, renal injury in cirrhosis, and porphyria, Dr. Singal’s research has been funded by the American College of Gastroenterology, National Institute of Health, and pharmaceutical industry. He has over 350 original peers reviewed articles in national / international journals and book chapters. In 2024, Dr. Singal was recruited to the top 2% of world scientists database which is created and maintained by Elsevier in collaboration with Stanford University. Dr. Singal’s editorial activities include Editorial board (Hepatology, Liver Transplantation, , CGH, JHEP Reports, Seminars Liver Disease) and Associate Editor (Clinical Translational Gastroenterology, Current Hepatology Reports, Digestive Liver Disease, Journal of Clinical Translational Hepatology, and Journal of Clinical and Experimental Hepatology).
Apart from reviewing research grants and scientific research abstracts for the AGA and AASLD, Dr. Singal is on the study section for the NIH. He is a lead author on ACG guidelines for alcoholic liver disease, co-authored guidelines on vascular disorders of the liver and nutritional management of patients with cirrhosis and revised guidelines on alcohol-associated liver disease. Dr. Singal has been awarded the prestigious Edgar Achkar Visiting Professorship by the ACG and Dr. Reddinger Lectureship at the University of Louisville. He has chaired the special interest group on alcohol-related liver disease (2020-2021) of the AASLD. He is the Advisor AASLD SIG Task Force and Chair of the Liver Biliary section of the AGA Council.
Mads Israelsen
Odense, Denmark
Aleksander Krag
Odense, Denmark
Aleksander Krag, MD, PhD, MBA is Professor and Department Chair, Department of Gastroenterology and Hepatology Odense University Hospital, Director of Centre for Liver Research (FLASH) Odense University Hospital and DIAS Chairof Health Sciences, University of Southern Denmark. He also served as Vice-Secretary and then as Secretary General of European Association for the Study of Liver (EASL) 2021-2025. Aleksander Krag is involved in and hold leader positions in a number of large research collaborations in liver diseases, including being director of FLASH: Fibrosis Fatty Liver and Steatohepatitis Research Centre Odense, PI in MicrobLiver, Coordinator in the H2020 project GALAXY: Gut and Liver Axis in Alcoholic Liver Fibrosis and partner and PI in the H2020/Horizon Europe projects MicrobPredict, LiverScreen, The International Human Microbiome Action and LiverAIM and PI in the Center of Excellence Center for Functional Genomics and Tissue Plasticity.
Juan Pablo Arab
Richmond, USA
Dr. Arab is Associate Professor of Medicine at the Division of Gastroenterology, Hepatology, and Nutrition of Virginia Commonwealth University School of Medicine. He serves as the Inaugural Director of Alcohol Sciences at the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health. Dr. Arab is an Associate Editor for Hepatology (flagship AASLD journal). He is currently the Chair of the Special Interest Group on ALD of the International Liver Transplantation Society (ILTS) and ALEH, Past Chair of AASLD, Chair of the Clinical Committee at the NIAAA-sponsored AlcHepNet. He has published more than 340 peer-reviewed papers, co-authored several book chapters and authored multiple clinical practice guidelines.
Christophe Moreno
Bruxelles, Belgium
Christophe Moreno is Professor of Hepato-Gastroenterology. He is chairman of the Department of Gastroenterology, Hepatopancreatology and Digestive Oncology in Hôpital Universitaire de Bruxelles since 2023. He completed his medical training in the Faculty of Medicine of the Université Libre de Bruxelles and achieved his PhD in the Laboratory of Experimental Gastroenterology (Université Libre de Bruxelles) in 2007, where he worked on the role of chemokine receptors in animal models of acute hepatitis and pancreatitis.
His clinical interests include alcohol-related liver disease, metabolic dysfunction-associated steatotic liver disease, complications of cirrhosis, viral hepatitis and liver transplantation. He is involved in both clinical and translational research.
His main topic in research is alcohol-related liver disease (natural history, treatment, liver transplantation, ethics).
Christophe Moreno has published more than 200 articles in prominent journals including the New England Journal of Medicine, JAMA, Journal of Hepatology, Gastroenterology, and Hepatology.
He was president of the Belgian Association for the study of the Liver (2017-2018), member of European Association for the Study of the Liver and the American Association for the Study of Liver disease.
He was Associate Editor for Journal of Hepatology (2014-2019) and for UEG Journal (2019-2024).
He is Chair of the EASL-SALVE (Study for Alcohol-related Liver disease in Europe) consortium since June 2024.
Nikhil Vergis
GSK
Dr Nikhil Vergis is Senior Director and a Clinical Development Leader at GSK in Hepatology. He has led clinical trials in SLD for multiple drugs at GSK. He was involved in the initiation of one of the first industry-sponsored trials in Alcohol-related Liver Disease – the STARLIGHT study. Prior to joining GSK, he was a Consultant Hepatologist at Imperial College NHS Trust and concurrently held a post-doctoral Fellowship with Imperial College London and the Wellcome Trust.
Nikhil has over 15 years’ experience in steatohepatitis research at Imperial College London. Areas of focus include immune dysfunction in steatohepatitis and the determinants and impact of alcohol-related hepatitis. Prior to joining industry, he led Phase 2 and Phase 3 university-sponsored clinical trials.
He continues to see patients with SLD in an integrated clinic at St Mary’s Hospital, London, and holds both Honorary Consultant Hepatologist and Honorary Clinical Senior Lecturer positions with Imperial College NHS Trust and Imperial College London, respectively.
Juan G Abraldes
Edmonton, Canada
Dr. Juan G. Abraldes is a Transplant Hepatologist, Professor and Director of the Liver Unit at the University of Alberta.
He gained his MD in 1995 from the University of Santiago de Compostela, Spain, and got his Board Certificate in Gastroenterology and Hepatology at the Liver Unit, Hospital Clinic, University of Barcelona (2000). He did a postdoctoral training at Yale University (2003–2004).
His main interest is the diagnosis, risk prediction and management of chronic liver disease. He is the co-author of the American Association for the Liver (AASLD) Clinical Guidance for the management of varices and variceal bleeding in cirrhosis 2016, and the chair of the AASLD guidance on TIPS and Endovascular Therapies for Variceal Hemorrhage 2024. He has contributed to Baveno guidelines for the management of portal hypertension since 2005. He is Associate Editor of Hepatology.
Gro Askgaard
Køge, Denmark
Gro Askgaard is a hepatologist and associate professor residing at Zealand University Hospital, Denmark. She has conducted epidemiological studies within the field of alcohol-related liver disease and cirrhosis describing alcohol risks and outcomes for patients. She is currently running RCTs of screening for chronic liver disease in individuals attending specialised AUD treatment in the community and of AUD treatment in the hospital setting for newly diagnosed patients with alcohol-related liver disease.
Paul N Brennan
Dundee, Scotland
Dr Brennan is a translationally-focused clinician, with broad research themes; spanning early identification of liver disease, epidemiology, public health and advanced therapeutics. He completed a clinical lectureship at the University of Dundee, doctoral studies at the Centre for Regenerative
Medicine, University of Edinburgh, and advanced transplant hepatology training in the Scottish Liver Transplant Unit.
He maintains a keen interest in the multimorbidity associated with steatotic liver disease, obesity/metabolic dysfunction, including cardiovascular and renal sequelae of disease. Additionally, he remains focused on the interface between MASLD and alcohol usage i.e. MetALD, or ArLD through novel biomarker usage.
He has an interest in early detection of advanced chronic liver disease in primary care and was a member of the Lancet Gastroenterology and Hepatology Commission on chronic liver disease in primary care.
Finally, he is an active member in a number of BASL Specialist Interest Groups and engages across a number of national and international collaboratives in developing large data cohorts and translational clinical trials, whilst developing public health policies to include liver disease within the NCD field. He is a member of the Global NASH council, a Co-I on the DiALS UK study for the detection of Cirrhosis in Primary Care, and as a scientific member of the Global Think Tank on SLD.
Luis Antonio Diaz
San Diego, USA
Dr. Díaz is currently an Assistant Professor at the Division of Gastroenterology and Hepatology, University of California San Diego (UCSD), and Assistant Professor at the Pontificia Universidad Católica de Chile (PUC). He is a Gastroenterologist and Internal Medicine specialist trained at the PUC, School of Medicine. He currently co-leads several multi-national studies regarding alcohol-associated liver disease, including STELLA and Global AlcHep Network. Currently, he is a member of the Steering Committee of the Alcohol-Associated Liver Disease (ALD) Special Interest Group (SIG) of the American Association for the Study of Liver Diseases (AASLD) and Chair of the ALD and Public Health SIGs for the Latin American Association for the Study of the Liver (ALEH).
Sven Francque
Antwerp, Belgium
Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital, Belgium and at the Department of Hepatology of the Beaujon hospital, Clichy, France. He has a long-standing interest and expertise in non-alcoholic fatty liver disease (NAFLD), currently metabolic dysfunction associated steatotic liver disease (MASLD) and conducted basic research focusing on the vascular changes in steatosis and steatohepatitis, and their contribution to disease progression, leading to his PhD in 2011. His research unit continues to study pathophysiological mechanisms of metabolic dysfunction associated steatohepatitis (MASH). He is also conducting clinical research and his unit is partner in several research consortia supported by the European Commission, by the Innovative Medicines Initiative and the Innovative Health Initiative with a focus on MASH pathophysiology, biomarker research and hepatocellular carcinoma. His clinical trial unit participates from the early days of clinical trials in MASH in many clinical trials in the field. Prof. Francque is as scientific committee member involved in the design of several phase 2 and current phase 3 trials in MASLD and is national and international lead PI of several of these trials.
He is author/co-author of over 300 papers in peer-reviewed journals and authored several book chapters on NAFLD/MASLD. He has been editor of JHep Reports, the open-access journal of the European Association for the Study of the Liver (EASL). He is senior clinical researcher for the Research Fund of the Flemish government. He is currently chairman of the Department of Gastroenterology and Hepatology of the University Hospital Antwerp and senior full professor of medicine at the Faculty of Medicine and Health Sciences of the University of Antwerp. He is scientific coordinator of the Belgian Week of Gastroenterology, the Belgian national research meeting of all scientific societies in gastroenterology and hepatology in Belgium. He coordinated the Belgian guidelines on NAFLD/MASLD and more recently the EASL and EASO-endorsed NAFLD/MASLD patient guideline. He was a working group lead on the nomenclature change for NAFLD and served on the committee of the recent EASL-EASD-EASO MASLD clinical practice guideline. He is member of the governing board of EASL as Educational Councillor.
Giacomo Germani
Padova, Italy
Medical Education:
Medical Degree at Padova University, Italy (2005).
Specialization on Gastroenterology and Endoscopy at Padova University, Italy (2010).
Clinical research fellow at the Royal Free Hospital in London, UK (2010-2013).
Doctoral degree in Hepatology and Regenerative Medicine in 2013 from the University of Padova.
Current Academic or Administrative Positions:
Head of Multivisceral Transplant Unit, Padova University Hospital, Italy.
Associate Professor of Gastroenterology, Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy.
Area of Research interests:
Clinical and translational studies in the setting of liver transplantation, mainly regarding alcohol-related liver disease, acute alcoholic hepatitis, liver transplantation for MASLD and MASH, acute liver failure, DILI and adherence before and after liver transplantation.
Publications and Presentations:
Author of more than 150 articles in international peer-reviewed journals, with an H-index of 42 and several presentations in national and international congresses.
Comments:
Current Secretary General of the Italian Association for the Study of the Liver (AISF)
Past Chair of the European Liver & Intestine Transplant Association (ELITA)
Member of the SIG on ALD of the International Liver Transplant Society (ILTS)
Member of the International Liver Transplant Society (ILTS) Educational Committee (2015-2018)
Member of the EASL young investigator Concerted Action Group (2013-2018).
Susana G Rodrigues
Bern, Schweiz
Susana G. Rodrigues, MD, PhD, is a Consultant Hepatologist at the University Clinic of Visceral Surgery and Medicine, Hepatology, Inselspital, Bern University Hospital, Switzerland, and researcher at the Department of Biomedical Research, University of Bern.
Her clinical and research expertise centers on portal hypertension, complications of liver cirrhosis, and, steatotic liver disease, namely, alcohol-related liver disease.
Camilla Dalby Hansen
Odense, Denmark
Peter Jepsen
Aarhus, Denmark
Morten Karsdal
Nordic Bioscience
PRIMARY EXPERTISE
Professor Karsdal is a distinguished researcher with extensive expertise in rheumatology (RA & OA), obesity, diabetes, and fibrosis. He has authored over 750 peer-reviewed publications in top journals. He has led the development of FDA-approved molecular diagnostics and over 125 commercialized ELISA assays. With his vast experience in clinical trial design and the use of biochemical markers in translational science, he has participated in more than 100 clinical studies.
Professor Karsdal has worked on various oral formulations of smaller proteins and has been involved in developing treatments for fibrosis, osteoporosis, osteoarthritis, obesity, and diabetes, from target identification through to phase III studies. He serves as an Adjunct Professor of Molecular Medicine at the Southern University of Denmark.
In 2016, he published his first book, Biochemistry of Collagens, Laminins and Elastin, which offers a comprehensive introduction to collagen and structural proteins. In 2021, he delivered his first TEDx talk on ECM and collagens, titled "I love collagens... and you should too."
SCIENTIFIC SUMMARY
750+ publications in peer reviewed journals; Karsdal@PubMed
44746 citations, H-index: 106, 4800 citations/year
Ph.D students mentored: 75
Awards: 9
Michelle Long
Novo Nordisk
Michelle T. Long, MD, MSc is the International Medical Vice President for MASH at Novo Nordisk where she supports the MASH and SLD clinical development projects and therapy area. Dr. Long has experience in clinical hepatologist and gastroenterologist and previously worked as a physician scientist at Boston University School of Medicine. She has expertise in the overlap between MASH and cardiometabolic disease, cirrhosis, epidemiology, biomarkers, risk stratification, and care pathways.
Gautam Mehta
London, United Kingdom
Gautam is a Hepatologist and Principal Investigator based at University College London (UCL). The mission of his work is to develop new treatments for patients with steatotic liver disease. He is the lead for the AlcoChange digital health clinical trial, and the SLIM-NET (SLD and machine learning) and UK-CLIF programmes.
Mack Mitchell
Dallas, USA
Dr. Mack C. Mitchell is Vice President for Medical Affairs and the Nancy and Jeremy Halbreich Professor of Gastroenterology at UT Southwestern Medical Center in Dallas, Texas. He previously served as interim Executive Vice President for the Health System at UT Southwestern, Director of Gastroenterology at Johns Hopkins Bayview Medical Center, and Chair of Medicine at Carolinas Medical Center in North Carolina.
Dr. Mitchell earned his M.D. and completed his residency in internal medicine at Johns Hopkins, followed by fellowships in gastroenterology and clinical pharmacology at Vanderbilt University. He is a Fellow of the American College of Physicians and the American Association for the Study of Liver Diseases.
Dr. Mitchell has served on the Advisory Council and as Chair of the Board of Scientific Councilors of the National Institute on Alcohol Abuse and Alcoholism. He is President of ABMRF, The Foundation for Alcohol Research, and leads the UT Southwestern research team as principal investigator for AlcHepNet, a multicenter NIH-sponsored clinical research study of alcohol-associated hepatitis. He has co-authored publications on alcohol-related liver injury, including the AGA guidelines on alcohol-associated hepatitis and the NIAAA-sponsored recommendations for designing clinical trials in alcohol use and alcohol-associated liver disease.
Richard Parker
Leeds, United Kingdom
Carolin Schneider
Aachen, Germany
Horia Stefanescu
Cluj-Napoca, Romania
Horia Stefanescu is curently senior hepatologist working at the Regional Institute of Gastroenterology and Hepatology in Cluj-Napoca, Romania. He obtained both is MD (2002) and his PhD (2012) degrees at the Cluj-Napoca University of Medicine and Pharmacy. His PhD research was focused on noninvasive assessment of chronic liver diseases, when he proposed and validated spleen stiffness measurement by transient elastography as surrogate for clinically significant portal hypertension and high-risk esophageal varices. In 2014/15 dr Stefanescu served as a post-doc researcher in the field of hepatology and liver ultrasound at the Department of Medical and Surgical Sciences at Bologna University (prof Fabio Piscaglia).
Horias’ research focus is alcohol related (and mixed, metabolic associated and alcohol related) liver disease, from public heath to patient centered perspectives. He is interested in the noninvasive prediction of liver related events, with a focus on elastography and multiparametric ultrasound and, in biomarker/therapeutic target discovery using translational approaches.
To date, Horia Stefanescu (co)authored more than 150 publications, his h-index being 30. He was also involved in 19 research projects (3 as PI), 14 clinical trials and he also managed 2 public heath projects in Romania. He is member of European and national hepatology and ultrasound associations. Within EASL he is acting as secretary of the SALVE consortium. He also serves as a reviewer for many of the highly cited journals in the field of liver diseases and ultrasound.
Stefan Stender
Copenhagen, Denmark
Dr. Stefan Stender is a consultant and associate professor at the Department of Clinical Biochemistry at Rigshospitalet, Copenhagen University Hospital, Denmark. His research leverages large-scale genetic studies to investigate gastrointestinal and cardiometabolic diseases. Most recently, he has spearheaded genome-wide association studies of cirrhosis and hepatocellular carcinoma. In addition to his clinical research, Dr. Stendercontributes to the international dialogue on scientific integrity, focusing on the challenges posed by paper mills and the misuse of AI.
Nikolaj Torp
Odense, Denmark
Nikolaj Torp, MD, PhD is a clinical researcher in hepatology with a particular focus on alcohol biomarkers and their application in chronic liver disease. His research has centered on the use of phosphatidylethanol (PEth) as an objective marker of alcohol consumption. His PhD focused on the use of PEth in steatotic liver disease, investigating its role in identifying alcohol intake beyond self-reported consumption and as a prognostic supplement to non-invasive tests. At AlcoMet 2026, he will discuss the role of PEth and other alcohol biomarkers in improving alcohol quantification and supporting clinical trial design in MetALD and ALD.
Gerald Scott Winder
Detroit, USA
Dr. Gerald Scott Winder is a senior staff physician in the Transplant Institute and Department of Psychiatry at Henry Ford Health as well as a Clinical Professor in the Departments of Psychiatry and Surgery at Michigan State University. He holds a medical degree from the University of Utah School of Medicine and a masters of science degree from the University of Michigan School of Public Health. He completed a general psychiatry residency and a consultation-liaison psychiatry fellowship at the University of Michigan. A consultation-liaison psychiatrist, Dr. Winder specializes in the psychiatric care of the medically ill. He has co-founded interdisciplinary clinics in organ transplantation, neurology, and hepatology.
Zobair M Younossi
Washington DC, USA
Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD is Chairman of the Global NASH/MASH Council, Professor of Medicine, and Chairman of the Global Center for Liver Outcomes & Policy Research at Georgetown University School of Medicine. He earned his MD from the University of Rochester (AOA, 1989), completed gastroenterology/hepatology fellowship at Scripps Clinic and Research Foundation (1989–1995), and obtained an MPH from San Diego State University (multiple honors 1995). After serving at Cleveland Clinic Foundation (1995–2000), he established Center for Liver Diseases and Beatty Liver and Obesity Research Program at Inova Health System, where he held roles including Chairman of Medicine, President of Inova Medicine, and Chairman of Research (2000-2026). He also serves as President of the Chronic Liver Disease Foundation. A pioneer in MASLD and liver outcomes research, he has authored 900 peer-reviewed publications, presented 1,220+ abstracts, and delivered 560+ invited lectures. With an H-index of 159 and 169,772 citations, ScholarGPS (2022–2025) ranks him the most cited scholar in liver disease.
Mary Rinella
Chicago, USA
Mary E. Rinella, MD is a Professor of Medicine in the Gastroenterology, Hepatology and Nutrition section at the University of Chicago since January 2021, where she is the director of the Metabolic and Fatty Liver Program as well as Director of Clinical trials.
She has held several national societal leadership roles, including on the Governing Board of the American Association for the Study of Liver Disease (AASLD). She was lead author of the 2023 AASLD Clinical Practice Guidance on the diagnosis and management of NAFLD, now MASLD. She led the multi-society global effort to revise the nomenclature of NAFLD and served as Chair of the AASLD Steatotic Liver Disease (SLD) task force, charged with increasing disease awareness, disseminating best practice, developing a national strategy and fortifying global collaborations to improve care and outcomes of patients with SLD. In addition to focusing on increasing disease awareness, she is actively involved in the development of new therapeutics for MASH and serves as a Global PI for prominent Phase 3 programs.
Ramon Bataller
Barcelona, Spain
Dr. Ramon Bataller is Chair of the Liver Unit at Hospital Clínic de Barcelona and Professor of Medicine at the Universitat de Barcelona, with an ongoing appointment as Adjunct Professor at the University of Pittsburgh, where he previously served as Chief of Hepatology (2017–2022). His research focuses on the pathogenesis and treatment of alcohol-related liver disease, with particular interest in biomarker development, and translational science. He has authored an extensive body of work in the field, attracted substantial competitive research funding, and maintains longstanding collaborative networks across leading US and European institutions. Dr. Bataller is also active in clinical trial advisory work in alcohol-associated hepatitis and continues to lead translational research through IDIBAPS in Barcelona.
Mattias Mandorfer
Vienna, Austria
Prof. Mandorfer studied Medicine in Vienna & Heidelberg and obtained his M.D. degree in 2012. He is a consultant in Internal Medicine (since 2018), Gastroenterology and Hepatology (since 2021), and Intensive Care (since 2023) and holds certificates in Interventional Endoscopy and Medical Education. In 2019, he stayed as a fellow at the Barcelona Hepatic Hemodynamic Lab.
He obtained his Ph.D.-equivalent degree in 2017, a junior faculty position in 2018, and is senior faculty (since 2021) at Medical University of Vienna where has been appointed head of the Vienna Hepatic Hemodynamic Lab and the SLD clinic.
Prof. Mandorfer is part of the Steering and Research Committees of the Baveno Cooperation (an EASL Consortium), for which also serves as treasurer. Moreover, he is the counsellor of CME and the head of the Hepatology section of the Austrian Society of Gastroenterology and Hepatology.
His main research interests are ACLD/cirrhosis, portal hypertension, minimally/non-invasive testing, and alpha-1 antitrypsin deficiency. He serves as an associate editor of JHEP Rep and is/was a member of the editorial boards of Gastroenterology, J Hepatol, Hepatology, Am J Gastroenterol, Liver Int, and Hepatol Comm. He received UEG’s Rising Star Award (2024) and EASL’s Emerging Leader Award (2025).